Skip to content
The U.S. Food and Drug Administration (FDA) announced the creation of its Rare Disease Innovation Hub in July 2024. With the goal of engaging […]
BIO makes recommendation for new FDA Rare Disease Innovation Hub Read More »
The Biotechnology Innovation Organization (BIO) has once again requested that the Centers for Medicare & Medicaid Services (CMS) take steps to protect patient access,
CMS must address Part D plan abuse of IRA provisions designed to protect patient access Read More »
Despite frequent criticism of the Federal Trade Commission (FTC), the Conservative Political Action Conference (CPAC) has announced its support for FTC efforts to rein in pharmacy
CPAC supports FTC action against pharmacy benefit managers Read More »
October is the scariest time of year. Young goblins walk the streets demanding treats, local haunted houses are packed full of fright-chasing teens, and
Open enrollment can be a ‘House of Horrors’: 4 monsters for patients to beware Read More »
Patient advocates from across the country gathered in Washington, D.C., on October 23-24 for the BIO Patient and Health Advocacy Summit (PHAS). This event
PHAS 2024: Patient advocates unite to share stories and address barriers to treatment Read More »
The 340B program grew by 24% in 2023, according to new figures from the government’s Health Resources and Services Administration. Sales at discounted prices
Skyrocketing 340B program spending must prompt more hospital accountability Read More »
X-Therma, a member of the Biotechnology Innovation Organization (BIO), is making significant headway in its fight to abolish the organ transplant list. With X-Therma’s
A cutting-edge biotech announces world’s first subzero transatlantic organ transports Read More »
A family battling rare disease, a biopharma startup they’re assisting, and an organization seeking congressional support for new rare disease drugs share their journeys
A family, a firm, and a foundation fighting rare disease join BIO’s podcast Read More »
The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined by the Inflation Reduction
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’ Read More »
“All of us have been paying attention and seeing the ‘AI high’ for the last several years,” said Ruchita Sinha, MBA, General Partner at
BIF 2024: AI experts discuss use cases, benefits, ROI Read More »
